FY2023 EPS Estimates for Pfizer Inc. Decreased by Analyst (NYSE:PFE)

Pfizer Inc. (NYSE:PFE – Get Rating) – Investment analysts at Cantor Fitzgerald dropped their FY2023 earnings estimates for Pfizer in a report released on Tuesday, January 17th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of $3.35 for the year, down from their previous forecast of $4.37. The consensus estimate for Pfizer’s current full-year earnings is $6.46 per share.

Pfizer (NYSE:PFE – Get Rating) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.31. Pfizer had a net margin of 29.81% and a return on equity of 43.95%. The firm had revenue of $22.64 billion during the quarter, compared to analysts’ expectations of $21.04 billion.

Other research analysts also recently issued research reports about the stock. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price target on the stock. in a research report on Wednesday, January 4th. UBS Group set a $55.00 target price on Pfizer in a research note on Wednesday. Barclays increased their target price on Pfizer from $44.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 2nd. Morgan Stanley upped their price target on Pfizer from $51.00 to $53.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 14th. Finally, SVB Leerink increased their price objective on Pfizer from $48.00 to $49.00 and gave the company a “market perform” rating in a report on Thursday, November 3rd. Seven analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $53.00.

Pfizer Trading Up 0.3 %

Shares of Pfizer stock opened at $45.11 on Friday. Pfizer has a 52-week low of $41.44 and a 52-week high of $56.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The company’s fifty day moving average price is $49.84 and its two-hundred day moving average price is $48.23. The firm has a market capitalization of $253.22 billion, a PE ratio of 8.68, a price-to-earnings-growth ratio of 1.13 and a beta of 0.67.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be issued a dividend of $0.41 per share. The ex-dividend date is Thursday, January 26th. This is a boost from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.64%. Pfizer’s dividend payout ratio is currently 30.77%.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of the stock. Lam Group Inc. bought a new position in Pfizer during the 4th quarter valued at approximately $25,000. Karp Capital Management Corp purchased a new position in shares of Pfizer in the 3rd quarter worth $27,000. Steward Financial Group LLC boosted its stake in shares of Pfizer by 315.3% in the 2nd quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 413 shares during the last quarter. Worth Asset Management LLC purchased a new position in shares of Pfizer in the 1st quarter worth $29,000. Finally, Goodman Advisory Group LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $32,000. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.